Abstract
Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Medicinal Chemistry
Title: The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers
Volume: 3 Issue: 6
Author(s): Allen B. Reitz, Suneel K. Gupta, Yifang Huang, Michael H. Parker and Richard R. Ryan
Affiliation:
Keywords: CHO cells, muscarinic receptors, desethyloxybutynin, oxybutynin therapy, binding assay
Abstract: Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence. The major metabolite of oxybutynin in humans is desethyloxybutynin (2). We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace N-CT3-scopolamine chloride (3H-NMS) binding on human cloned muscarinic m1-5 receptors. Compounds 1 and 2 potently displaced 3H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes. However, metabolite 2 was more potent than the parent compound 1 in the binding assay. In general the R enantiomers were more potent than their respective S enantiomers. Therefore, we suggest that the cholinergic side effects associated with 2 may be due to its greater apparent potency with m1 and m3 receptors, especially of its R-enantiomer, when compared with parent drug 1.
Export Options
About this article
Cite this article as:
Reitz B. Allen, Gupta K. Suneel, Huang Yifang, Parker H. Michael and Ryan R. Richard, The Preparation and Human Muscarinic Receptor Profiling of Oxybutynin and N-Desethyloxybutynin Enantiomers, Medicinal Chemistry 2007; 3 (6) . https://dx.doi.org/10.2174/157340607782360353
DOI https://dx.doi.org/10.2174/157340607782360353 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry The Fight Against Drug-Resistant Malaria: Novel Plasmodial Targets and Antimalarial Drugs
Current Medicinal Chemistry L-Carnosine Modulates Respiratory Burst and Reactive Oxygen Species Production in Neutrophil Biochemistry and Function: May Oral Dosage Form of Non-Hydrolized Dipeptide L-Carnosine Complement Anti-Infective Anti-Influenza Flu Treatment, Prevention and Self-Care as an Alternative to the Conventional Vaccination?
Current Clinical Pharmacology Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Pharmacokinetic Properties and In Silico ADME Modeling in Drug Discovery
Medicinal Chemistry Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy Inflammatory Mechanisms of Injury and Recovery after Intracerebral Hemorrhage
Current Immunology Reviews (Discontinued) Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450
Current Drug Metabolism Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Matrix Metalloproteinase Dependent Cleavage of Cell Adhesion Molecules in the Pathogenesis of CNS Dysfunction with HIV and Methamphetamine
Current HIV Research Multi-Drug Resistant Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Viruses in Semen and Male Genital Tissues - Consequences for the Reproductive System and Therapeutic Perspectives
Current Pharmaceutical Design Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
CNS & Neurological Disorders - Drug Targets Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Editorial (Thematic Issue: Therapeutic Applications of Advanced Drug Delivery Systems)
Current Pharmaceutical Design